AbbVie Inc. Trade and Non-Trade Receivables Growth

Trade and Non-Trade Receivables Growth of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Trade and Non-Trade Receivables Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Trade and Non-Trade Receivables Growth for the quarter ending September 29, 2019 was -0.04 (a -19.18% decrease compared to previous quarter)
  • Year-over-year quarterly Trade and Non-Trade Receivables Growth decreased by -174.57%
  • Annual Trade and Non-Trade Receivables Growth for 2018 was 0.06 (a -16.14% decrease from previous year)
  • Annual Trade and Non-Trade Receivables Growth for 2017 was 0.07 (a 1076.27% increase from previous year)
  • Annual Trade and Non-Trade Receivables Growth for 2016 was 0.01 (a -97.79% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Trade and Non-Trade Receivables Growth of AbbVie Inc.

Most recent Trade and Non-Trade Receivables Growthof ABBV including historical data for past 10 years.

Interactive Chart of Trade and Non-Trade Receivables Growth of AbbVie Inc.

AbbVie Inc. Trade and Non-Trade Receivables Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -0.04 -0.05 -0.03
2018 0.06 0.18 0.19 0.25 0.06
2017 0.07 -0.02 -0.04 -0.02 0.07
2016 0.01 0.09 0.16 0.09 0.01
2015 0.27 0.14 0.15 -0.05 0.27
2014 -0.22 0.05 0.01 0.07 -0.22
2013 0.12 0.23 0.25 0.18 0.12
2012 0.13 -0.08 0.13
2011 0.13

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.